Rhumbline Advisers Purchases 4,127 Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO)

Rhumbline Advisers lifted its stake in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) by 19.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 25,197 shares of the company’s stock after buying an additional 4,127 shares during the period. Rhumbline Advisers owned approximately 0.08% of Lexeo Therapeutics worth $166,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also made changes to their positions in the stock. Charles Schwab Investment Management Inc. lifted its stake in Lexeo Therapeutics by 107.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 63,874 shares of the company’s stock worth $577,000 after purchasing an additional 33,013 shares during the last quarter. BNP Paribas Financial Markets increased its holdings in Lexeo Therapeutics by 184.2% in the third quarter. BNP Paribas Financial Markets now owns 5,541 shares of the company’s stock valued at $50,000 after purchasing an additional 3,591 shares during the period. MetLife Investment Management LLC increased its holdings in Lexeo Therapeutics by 121.5% in the third quarter. MetLife Investment Management LLC now owns 14,223 shares of the company’s stock valued at $129,000 after purchasing an additional 7,803 shares during the period. Vestal Point Capital LP increased its holdings in Lexeo Therapeutics by 1.2% in the third quarter. Vestal Point Capital LP now owns 850,000 shares of the company’s stock valued at $7,684,000 after purchasing an additional 10,000 shares during the period. Finally, Verition Fund Management LLC increased its holdings in Lexeo Therapeutics by 84.5% in the third quarter. Verition Fund Management LLC now owns 777,320 shares of the company’s stock valued at $7,027,000 after purchasing an additional 355,928 shares during the period. 60.67% of the stock is currently owned by institutional investors.

Lexeo Therapeutics Trading Down 3.0 %

NASDAQ:LXEO opened at $2.62 on Tuesday. The firm has a 50-day moving average price of $4.90 and a two-hundred day moving average price of $7.30. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.95 and a current ratio of 5.95. Lexeo Therapeutics, Inc. has a 52 week low of $2.32 and a 52 week high of $19.50. The firm has a market cap of $86.63 million, a price-to-earnings ratio of -0.83 and a beta of 3.85.

Analysts Set New Price Targets

A number of analysts have weighed in on the company. Royal Bank of Canada reiterated an “outperform” rating and set a $24.00 price target on shares of Lexeo Therapeutics in a report on Tuesday, January 21st. Leerink Partners decreased their price objective on shares of Lexeo Therapeutics from $20.00 to $19.00 and set an “outperform” rating for the company in a research note on Wednesday, November 13th. HC Wainwright increased their price objective on shares of Lexeo Therapeutics from $21.00 to $23.00 and gave the company a “buy” rating in a research note on Thursday, November 14th. Finally, Chardan Capital increased their price objective on shares of Lexeo Therapeutics from $23.00 to $25.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. Five investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $23.80.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.